Evidence map›Paper›PMID 36319575›Full record

ArticleEuropean journal of haematology2023

Management of polycythemia vera: A survey of treatment patterns in Italy.

Giuseppe Alberto Palumbo, Massimo Breccia, Claudia Baratè, Massimiliano Bonifacio, Elena Maria Elli, Alessandra Iurlo, Novella Pugliese, Elena Rossi, Paola Guglielmelli, Francesca Palandri

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of haematology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 10 institutions in 1 country.

Giuseppe Alberto PalumboDipartimento di Scienze Mediche, Chirurgiche e Tecnologie Avanzate "G.F. Ingrassia", University of Catania, Catania, Italy.ORCID https://orcid.org/0000-0003-1859-6319
Massimo BrecciaHematology, Department of Precision and Translational Medicine, Policlinico Umberto 1, Sapienza University, Rome, Italy.ORCID https://orcid.org/0000-0003-1163-6162
Claudia BaratèDepartment of Clinical and Experimental Medicine, Section of Hematology, University of Pisa, Pisa, Italy.
Massimiliano BonifacioDepartment of Medicine, Section of Hematology, University of Verona and AOUI Verona, Verona, Italy.
Elena Maria ElliHematology Division and Bone Marrow Transplant Unit, Ospedale San Gerardo, ASST Monza, Monza, Italy.ORCID https://orcid.org/0000-0001-5576-5412
Alessandra IurloHematology Division, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.ORCID https://orcid.org/0000-0002-4401-0812
Novella PuglieseDepartment of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.
Elena RossiSection of Hematology, Department of Radiological and Hematological Sciences, Catholic University, Fondazione Policlinico A. Gemelli IRCCS, Rome, Italy.
Paola GuglielmelliCenter of Research and Innovation of Myeloproliferative Neoplasms, AOU Careggi, University of Florence, Florence, Italy.
Francesca PalandriIRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia "Seràgnoli", Bologna, Italy.
Agostino Gemelli University Polyclinic · ITAzienda Ospedaliera San Gerardo · ITAzienda Ospedaliero-Universitaria Careggi · ITFondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico · ITIstituto di Ematologia di Bologna · ITPoliclinico Umberto I · ITUniversity of Catania · ITUniversity of Naples Federico II · ITUniversity of Pisa · ITUniversity of Verona · IT

Funding

Novartis Farma SpA
6 · The paper itself

Abstract

objectivesPolycythemia vera (PV) is an acquired clonal hematopoietic stem cell disorder characterized by the overproduction of red blood cells. It has long been underlined that there are differences in treatment patterns in routine practice. Therapeutic strategies have also expanded, and in recent years the JAK1/JAK2 inhibitor ruxolitinib has emerged as a second-line therapeutic option in patients who are intolerant to or resistant to hydroxyurea. Determining the impact of changes on practice patterns is of interest, especially for aspects that lack detailed guidance for management.

methodsTo gain insights into treatment patterns by clinicians treating patients with PV in Italy, we carried out a survey of 60 hematologists and transfusion specialists. The questions covered: treatment of low-risk patients, definition of significant leukocytosis, splenomegaly and excessive phlebotomies, resistance/intolerance to hydroxyurea, use of ruxolitinib, cytoreductive therapy, and vaccines.

resultsIn general, the results of the survey indicate that there is a large heterogeneity in management of patients with PV across these areas.

conclusionsWhile helping to provide greater understanding of treatment patterns for patients with PV in Italy, our survey highlights the need for additional clinical studies to obtain more precise guidance for the routine care of patients with PV.

Indexed as

Janus Kinase InhibitorsPolycythemia VeraHumansHydroxyureaItalyJanus Kinase 2NitrilesPyrazolesPyrimidinesHydroxyureaJanus Kinase 2Janus Kinase InhibitorsNitrilesPyrazolesPyrimidinesruxolitinibmanagementpatternspolycythemia verasurveytreatment

Identifiers

PMID36319575
PMCPMC10100449
OpenAlexW4307969126

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.